



12-12-05

IPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Laszlo Czollner et al. Attorney Docket: SAN1006US

Serial No: 10/647,283 Group Art Unit: 1624

Filed: August 26, 2003 Examiner: Bruck Kifle

For: BENZAZEPINE DERIVATIVES, DRUGS CONTAINING
THESE AND USE OF THE SAME FOR PRODUCING DRUGS

TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Transmitted herewith are the following:

1. Supplemental Information Disclosure Statement (2 pages);
2. Form 1449 listing 17 documents (1 page);
3. Copies of each of the non-U.S. documents listed on Form 1449 (12 documents); and
4. A check in the amount of \$180.00 to cover the fee under 37 C.F.R. § 1.97(c) for the submission of this Supplemental Information Disclosure Statement.

It is believed that no fees are due in connection with this submission. However if this is incorrect, please charge any additional fees to Deposit Account Number 16-2312.

Respectfully submitted,

Date: December 9, 2005

By



Customer No. 009561

Patrick J. O'Connell (33,984)
POPOVICH, WILES & O'CONNELL, P.A.
650 Third Avenue South, Suite 600
Minneapolis, MN 55402
Telephone: (612) 334-8989
Attorney for Applicants

Certificate of Express Mailing (37 C.F.R. § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. EV 769992035 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: December 9, 2005

Signature: 

Name: Jodi Jung



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Laszlo Czollner et al. Attorney Docket: SAN1006US

Serial No: 10/647,283 Group Art Unit: 1624

Filed: August 26, 2003 Examiner: Bruck Kifle

For: BENZAZEPINE DERIVATIVES, DRUGS CONTAINING
THESE AND USE OF THE SAME FOR PRODUCING DRUGS

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to Sections 1.56, 1.97, and 1.98 of Title 37 of the Code of Federal Regulations, the following information is set forth in compliance with Applicants' duty of disclosure, as well as the duty of others substantively involved in the preparation of the above-titled application.

The Applicants and others substantively involved in the preparation of the application are aware of the documents listed on the enclosed PTO-1449 form.

Copies of the non-U.S. documents are enclosed.

The present statement reflects the direct knowledge of the undersigned and information disclosed to the undersigned by the Applicants and others substantively involved in the preparation of the present application pursuant to their duty under 37 C.F.R. § 1.56.


12/14/2005 DTESEM1 00000092 10647283

01 FC:1806

180.00 UP Certificate of Express Mailing (37 C.F.R. § 1.10)

I hereby certify that this paper or fee is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" Mailing Label No. EV 769992035 US in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date indicated below.

Date: December 9, 2005

Signature: 

Name: Jodi Jung

Applicants reserve the right to show, pursuant to 37 C.F.R. § 1.131 or otherwise, that any one or more of the documents listed on the PTO-1449 form is not prior art to the present invention.


Pursuant to the Manual of Patent Examining Procedure, Chapter 609, Applicants request that the Examiner consider each of the listed documents and initial and return to the undersigned a copy of the enclosed PTO-1449 form.

A check in the amount of \$180.00 is enclosed to cover the fee under 37 C.F.R. § 1.97(c) for the submission of this Supplemental Information Disclosure Statement. It is believed that no fees are due in connection with this submission. However if this is incorrect, please charge any additional fees to Deposit Account Number 16-2312.

Respectfully submitted,

Date: December 9, 2005

By



Customer No. 009561

Patrick J. O'Connell (33,984)


POPOVICH, WILES & O'CONNELL, P.A.

650 Third Avenue South, Suite 600

Minneapolis, MN 55402

Telephone: (612) 334-8989

Attorney for Applicants



FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

SERIAL NO.

SAN1006US

10/647,283

APPLICANTS

Laszlo Czollner et al.

FILING DATE

GROUP

August 26, 2003

1624

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER							DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
5	1	5	3	1	9	3	10/06/92	Flanagan et al.				
6	3	6	9	2	3	8	04/09/02	Czollner et al.				
6	4	0	7	2	2	9	06/18/02	Czollner et al.				
6	6	3	8	9	2	5	10/28/03	Czollner et al.				

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
	AT 401 058 B	06/25/96	Austria			
	WO 88/08708	11/17/88	WIPO			
	WO 97/11078	03/27/97	WIPO			
	WO 00/32199 (abstract only)	06/08/00	WIPO			
	WO 00/32199	06/08/00	WIPO			
	WO 2005/030333 A2 (abstract only)	04/07/05	WIPO			
	WO 2005/030333 A2	04/07/05	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Bastida et al., "Narcissus Alkaloids. Part 19. Alkaloids from Narcissus Leonensis," <i>Phytochemistry</i> , 34(6):1656-1658, XP001009775 (1993).
		Pilger et al., "Accurate Prediction of the Bound Conformation of Galanthamine in the Active Site of <i>Torpedo California</i> Acetylcholinesterase Using Molecular Docking," <i>J. Molecular Graphics and Modeling</i> , 19:288-296 (2001).
		Pokorna et al., "Capillary Zone Electrophoresis Determination of Galanthamine in Biological Fluids and Pharmaceutical Preparatives: Experimental Design and Artificial Neural Network Optimization," <i>Electrophoresis</i> , 19, 20, 1993-1997.
		Poschalko et al., "Synthesis of (+)-6H-benzofuro[3a,3,2,ef][3]benzazepine: an unnatural analog of (-)galanthamine," <i>Tetrahedron</i> , 58:1513-1518 (2002).
		Roques et al., "Structure of Norgalanthamine Hydrochloride," <i>ACTA CRYSTALLOGR.</i> , Sect. B, B36(7):1589-1593, XP001009771 (1980).
		U.S. Patent Application Publication No. 2003/0199493 A1, October 23, 2003, Jordis et al.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.